Novel inhibitor of soluble epoxide hydrolase (IC50=18nM and 69nM for the mouse and human enzymes respectively). Produces a hypotensive effect in angiotensin-infused rats and prevents and reverses cardiac hypertrophy in mouse models of cardiac hypertrophy.
Product Details
| Alternative Name: | 12-(3-Adamantan-1-yl-ureido)-dodecanoic acid |
| |
| Formula: | C21H36N2O3 |
| |
| MW: | 392.5753 |
| |
| CAS: | 479413-70-2 |
| |
| Purity: | ≥98% (TLC) |
| |
| Appearance: | White solid. |
| |
| Solubility: | Soluble in DMSO (10mg/ml) or 100% ethanol (4mg/ml). |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | -20°C |
| |
| Use/Stability: | Store solutions at -20°C for up to 3 months. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors: D. Xu, et al.; PNAS U.S.A.
103, 18733 (2006),
Abstract;
An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension: J.D. Imig, et al.; Hypertension
46, 975 (2005),
Abstract;
Structural refinement of inhibitors of urea-based soluble epoxide hydrolases: C. Morisseau, et al.; Biochem. Pharmacol.
63, 1599 (2002),
Abstract;
